Michael Severino - May 6, 2022 Form 4 Insider Report for AbbVie Inc. (ABBV)

Signature
Steven L. Scrogham, attorney-in-fact for Michael Severino
Stock symbol
ABBV
Transactions as of
May 6, 2022
Transactions value $
-$45,336,288
Form type
4
Date filed
5/10/2022, 05:05 PM
Previous filing
Apr 5, 2022
Next filing
May 16, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABBV Common Stock, $0.01 par value Options Exercise $4.05M +74.3K +48.85% $54.44 226K May 6, 2022 Direct
transaction ABBV Common Stock, $0.01 par value Options Exercise $1.41M +25.7K +11.35% $54.86 252K May 6, 2022 Direct
transaction ABBV Common Stock, $0.01 par value Sale -$6.03M -40.2K -15.94% $150.10 212K May 6, 2022 Direct F1
transaction ABBV Common Stock, $0.01 par value Sale -$6.95M -46K -21.7% $151.13 166K May 6, 2022 Direct F2
transaction ABBV Common Stock, $0.01 par value Sale -$2.1M -13.8K -8.34% $151.78 152K May 6, 2022 Direct F3
transaction ABBV Common Stock, $0.01 par value Options Exercise $3.64M +66.3K +43.59% $54.86 218K May 9, 2022 Direct
transaction ABBV Common Stock, $0.01 par value Options Exercise $1.98M +33.7K +15.43% $58.88 252K May 9, 2022 Direct
transaction ABBV Common Stock, $0.01 par value Sale -$7.06M -47.2K -18.73% $149.53 205K May 9, 2022 Direct F4
transaction ABBV Common Stock, $0.01 par value Sale -$4.78M -31.7K -15.48% $150.63 173K May 9, 2022 Direct F5
transaction ABBV Common Stock, $0.01 par value Sale -$3.19M -21.1K -12.17% $151.42 152K May 9, 2022 Direct F6
transaction ABBV Common Stock, $0.01 par value Options Exercise $4.17M +70.8K +46.53% $58.88 223K May 10, 2022 Direct
transaction ABBV Common Stock, $0.01 par value Options Exercise $1.79M +29.2K +13.11% $61.36 252K May 10, 2022 Direct
transaction ABBV Common Stock, $0.01 par value Sale -$3.46M -22.9K -9.07% $151.16 229K May 10, 2022 Direct F7
transaction ABBV Common Stock, $0.01 par value Sale -$4.34M -28.5K -12.45% $152.24 201K May 10, 2022 Direct F8
transaction ABBV Common Stock, $0.01 par value Sale -$7.43M -48.6K -24.21% $152.83 152K May 10, 2022 Direct F9

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABBV Option (Right to Buy) Options Exercise -$4.05M -74.3K -100% $54.44 0 May 6, 2022 Common Stock 74.3K $54.44 Direct F10
transaction ABBV Option (Right to Buy) Options Exercise -$1.41M -25.7K -27.93% $54.86 66.3K May 6, 2022 Common Stock 25.7K $54.86 Direct F10
transaction ABBV Option (Right to Buy) Options Exercise -$3.64M -66.3K -100% $54.86 0 May 9, 2022 Common Stock 66.3K $54.86 Direct F10
transaction ABBV Option (Right to Buy) Options Exercise -$1.98M -33.7K -32.26% $58.88 70.8K May 9, 2022 Common Stock 33.7K $58.88 Direct F10
transaction ABBV Option (Right to Buy) Options Exercise -$4.17M -70.8K -100% $58.88 0 May 10, 2022 Common Stock 70.8K $58.88 Direct F10
transaction ABBV Option (Right to Buy) Options Exercise -$1.79M -29.2K -29.19% $61.36 70.9K May 10, 2022 Common Stock 29.2K $61.36 Direct F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.58 to $150.57 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.58 to $151.57 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.58 to $151.95 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.04 to $150.03 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.04 to $151.03 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.04 to $151.93 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.55 to $151.54 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.55 to $152.54 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F9 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.55 to $153.50 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F10 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

Remarks:

The option exercise and sale transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).